Evidence-Based Complementary and Alternative Medicine

Evidence-Based Complementary and Alternative Medicine / 2016 / Article

Research Article | Open Access

Volume 2016 |Article ID 5989681 | 12 pages | https://doi.org/10.1155/2016/5989681

Activation of p53/miR-34a Tumor Suppressor Axis by Chinese Herbal Formula JP-1 in A549 Lung Adenocarcinoma Cells

Academic Editor: Yew-Min Tzeng
Received07 Aug 2016
Accepted14 Nov 2016
Published18 Dec 2016


Lung cancer is the leading cause of cancer death worldwide; the most common pathologic type is lung adenocarcinoma (LADC). In spite of the recent progress in targeted therapy, most LADC patients eventually expired due to the inevitable recurrence and drug resistance. New complementary agent with evidence-based molecular mechanism is urgently needed. MiR-34a is an important p53 downstream tumor suppressor, which regulates apoptosis, cell-cycle, EMT (epithelial mesenchymal transition), and so forth. Its expression is deficient in many types of cancers including LADC. Here, we show that a Chinese herbal formula JP-1 activates p53/miR-34a axis in A549 human LADC cells (p53 wild-type). Treatment with JP-1 induces p53 and its downstream p21 and BAX proteins as well as the miR-34a, resulting in growth inhibition, colony formation reduction, migration repression, and apoptosis induction. Accordingly, the decreases of miR-34a downstream targets such as CDK6, SIRT1, c-Myc, survivin, Snail, and AXL were observed. Moreover, JP-1 activates AMPKα and reduces mTOR activity, implying its inhibitory effect on the energy-sensitive protein synthesis and cell proliferation signaling. Our results show that JP-1 activates p53/miR-34a tumor suppressor axis and decreases proteins related to proliferation, apoptosis resistance, and metastasis, suggesting its potential as a complementary medicine for LADC treatment.

1. Introduction

Lung cancer is the most common cancer and remains the leading cause of cancer-related mortality worldwide [1, 2]. The most commonly diagnosed type is lung adenocarcinoma (LADC), which has a poor prognosis [3]. Even though various methods for diagnosis and treatment have been improved in recent decades, the 5-year survival rate of LADC is still unsatisfied [4]. There is a pressing need for new approaches to tackle this disease. In addition to the development of synthetic cytotoxic compounds or tyrosine kinase inhibitors, patients resort to complementary and alternative medicines for improving clinical outcomes. In this regard, Chinese herbal medicine with anticancer activities and low toxicity represents a viable resource and potential candidate.

The powerful tumor suppressor p53 is a transcription factor, which plays a crucial role in the regulation of cell-cycle, apoptosis, DNA repair, senescence, and angiogenesis [5]. Although the function of p53 is impaired in approximately half of human cancers by deletion or mutation of the gene encoding p53 protein, TP53 [5], it is still regarded as an important therapeutic target in oncology [6]. In the remaining 50% of human cancers with wild-type p53 status, blocking the negative regulation of p53 by MDM2 (human murine double minute 2) has become a promising cancer therapeutic strategy [5, 6]. A variety of small molecule or peptidic compounds had been developed to inhibit MDM2 [7]. On the other hand, many herbal extracts have been shown to induce growth arrest or apoptosis of cancer cells via p53 activation [813]. Thus, the Chinese herbal medicine represents a potential resource for searching for proper agent to restore p53 function of cancer cells.

JP-1 is a Chinese herbal formula developed by Dr. Peter Sheng, a medical oncologist in Cincinnati, Ohio, USA, which mainly consists of Ganoderma lucidum, Herba Scutellaria barbata, Scutellaria baicalensis, Oldenlandia diffusa, Astragalus membranaceus, Codonopsis Pilosula, and Bulbus fritillariae cirrhosae, and so forth. Based on Dr. Sheng’s clinical observation (unpublished data), JP-1 showed the effects to stabilize the tumor progression of chemotherapy-refractory patients with LADC and improved their quality of life, implying its potential as a complementary medicine. However, its mechanism of action has not yet been investigated. We attempt to explore the effects of JP-1 on LADC cells to evaluate its anticancer activities and elucidate the underlying molecular mechanisms.

Activation of p53 leads to transactivation of its target genes, like p21, BAX, Fas, and so forth, leading to growth arrest or apoptosis of cancer cells [14]. Recently, several studies have revealed microRNA (miR) components in the p53 tumor suppressor network [15]. MiRs are a recently identified large family of 21–25-nucleotide noncoding RNAs that regulate gene expression by targeting mRNA in a sequence-specific manner, resulting in either reduced translation efficiency or cleavage of the target mRNAs [16]. In recent years, miRs have received great attention in the research of LADC. Many miRs are misregulated in LADC and expected to play critical roles in the proliferation, metastasis, and chemoresistance [17, 18]. MiR-34a, a bona fide p53 transcriptional target, has been shown to inhibit genes, such as CDK6, SIRT1, c-Myc, survivin, Snail, and AXL, involved in cell-cycle progression, apoptosis resistance and epithelial mesenchymal transition (EMT), and so forth, [1921]. The expression of miR-34a is downregulated in many human cancers including lung cancer [22] and restoration of miR-34a results in tumor repression in mouse models of LADC [23, 24]. These observations imply that modulation of miR-34a expression might be a potential novel strategy to treat LADC.

In an attempt to investigate the molecular mechanism underlying JP-1-mediated anticancer activities, we explored its effects on the p53/miR-34a tumor suppressor axis in A549 human LADC cells harboring wild-type p53 gene. Our results show that JP-1 upregulates p53 protein level to increase those of p21 and BAX, resulting in growth arrest and apoptosis of A549 cells. Of note, the transcription of miR-34a is activated by JP-1 and the downstream targets of miR-34a such as CDK6, SIRT1, c-Myc, survivin, Snail, and AXL are repressed accordingly. Our findings suggest the effects of JP-1 on the activation of p53/miR-34a tumor suppressor axis, which may explain the clinical benefit observed in JP-1-treated patients.

2. Materials and Methods

2.1. Cell Culture

The A549 human lung adenocarcinoma cells and HS68 primary human fetal foreskin fibroblast cells were purchased from the American Type Culture Collection (Manassas, VA, USA). A549 cells were maintained in RPMI1640 and HS68 cells were in DMEM. Both mediums were supplemented with 10% fetal bovine serum (Caisson, North Logan, UT, USA), 1x penicillin-streptomycin-glutamine (Corning, Manassas, VA, USA), and 1x nonessential amino acids (Corning, Manassas, VA, USA). Cells were cultured at 37°C in a water-jacketed 5% CO2 incubator.

2.2. Preparation of JP-1

The original JP-1 powder was provided by Dr. Peter Sheng, a medical oncologist in Cincinnati, Ohio, USA. It was extracted by 38% ethanol. After lyophilization, the stock solution of JP-1 dissolved in ethanol at concentration 100 mg/mL was prepared. It was diluted in sterile culture medium immediately prior to use. The final concentrations of ethanol were all below 0.1%.

2.3. Cell Viability Assay by Sulforhodamine B (SRB) Staining

A549 cells were seeded in a 96-well plate at a density of 1.5 × 103 cells/well in 10% FBS-RPMI medium. HS68 cells were seeded in a 96-well plate at a density of 8 × 103 cells/well in 10% FBS-DMEM medium. After 24 h of incubation, cells were treated with various doses of JP-1 for another 72 h. Cells were then harvested and fixed by 10% trichloroacetic acid (TCA). After fixing, cells were washed by distilled water and stained viable cells by 0.4% (w/v) SRB dye dissolved in 1% acetic acid. After staining for 30 min, the unbound dye was then washed away by 1% acetic acid and the plate was air-dried. The cell-bound SRB dye was then dissolved in 200 μL of 10 mM Tris base and the absorbance was read on a microplate reader (BioTek ELx800, Winooski, VT, USA) at a wavelength of 570 nm. The absorbance was directly proportional to the cell number over a wide range.

2.4. Cell-Cycle Analysis

A total of 4 × 105 A549 cells/10 cm dish were incubated for 24 h after seeding and then treated with the indicated doses of JP-1 for another 48 h. Cells treated with culture medium only were used as a control. On the day of harvest, the cells were trypsinized using Trypsin-EDTA (Invitrogen) and washed twice with ice-cold PBS and then fixed in cold 70% ethanol for overnight at 4°C. Cells were washed twice with PBS after centrifuging at 200 ×g for 10 min and incubated with 100 μg/mL of PI (propidium iodide) and 100 μg/mL RNAse together at 37°C for 30 min and then transferred onto ice or stored at 4°C protected from light. The percentage of cells at different phases of cell-cycle was then measured by flow cytometer (Beckman Coulter EPICS XL, Fullerton, CA, USA).

2.5. Colony Formation Assay

A549 cells were seeded onto 6-well pates at a density of 200 cells per well. After 24 h, cells were treated with 75 and 150 μg/mL of JP-1, respectively. After 10 days of treatment, colonies were stained with Amido black and the number of colonies containing more than 50 cells was counted.

2.6. Semiquantitative Reverse-Transcription Polymerase Chain Reaction (RT-PCR)

A total of 4 × 105 A549 cells/10 cm dish were incubated for 24 h after seeding and then treated with variable doses of JP-1 for another 48 h. Total RNA was extracted using TRIzol reagent according to the manufacturer’s instructions and was reversely transcribed to cDNA by First-Strand cDNA Synthesis Kit (Fermentas, Lithuania). The PCR was carried out in a 50 μL reaction mixture that contained 1 μL of cDNA as template, 1 μM specific oligonucleotide primer pair, and 25 μL Taq mixture containing 0.5 unit of Taq DNA polymerase. The PCR primers used for amplification were as follows: miR-34a forward primer 5′-TTTCCTTCTTAT CAACAGGTGCT-3′ and miR-34a reverse primer 5′-ATCTCTCGCTTCATCTTCCCTCT-3′; U6 forward primer 5′-CTCGCTTCGGCAGCACA-3′ and U6 reverse primer 5′-AACGCTTCAC GAATTTGCGT-3′. PCR products were run on 1.5% agarose gels for identification.

2.7. Western Blotting

A total of 4 × 105 A549 cells/10 cm dish were incubated for 24 h after seeding and then were treated with variable doses of JP-1 as indicated in figures. On the day of harvest, the whole-cell lysates were prepared with 1x radioimmunoprecipitation (RIPA) lysis buffer (Millipore, Billerica, MA, USA) containing 1x tyrosine phosphatase inhibitor cocktail (FC0020-0001, BIONOVAS, Toronto, Canada), 1x protease inhibitor cocktail-full range (FC0070-0001, BIONOVAS, Toronto, Canada), and 1x serine/threonine phosphatase inhibitor cocktail (FC0030-0001, BIONOVAS, Toronto, Canada).

Samples (10 μg) of protein extract were size fractionated electrophoretically by 10% polyacrylamide SDS-PAGE gel and transferred onto a PVDF membrane using the BioRad Mini Protean electrotransfer system (CA, USA). The membranes blots were incubated with 5% milk in PBST for 1 h to block nonspecific binding and then were incubated with primary antibodies overnight at 4°C. The membranes were detected with an appropriate peroxidase-conjugated secondary antibody incubated at room temperature for 1 h. Intensive PBS washing was performed after each time of incubation. The immune complexes were visualized using an enhanced chemiluminescence detection system (ECL, Perkin Elmer, Waltham, MA, USA) according to the manufacturer’s instructions. Primary antibodies against BAX (1 : 1000, ab32503), CDK6 (1 : 1000, ab124821), GAPDH (1 : 1000, ab8245), p21 (1 : 1000, ab109199), p-mTOR (phospho S2448) (1 : 1000, ab109268), and Vimentin (1 : 1000, ab92547) were purchased from Abcam (Cambridge, MA, USA); primary antibodies for cleaved PARP (1 : 1000, #5625), cleaved caspase-9 (1 : 1000, #7237), cleaved caspase-3 (1 : 1000, #9664), p-AMPKα (Thr172) (1 : 1000, #2535), p-pRb (1 : 1000, #9308), SIRT1 (1 : 1000, #8469), survivin (1 : 1000, #2808), and Snail (1 : 1000, #3879) were purchased from Cell Signaling (Danvers, MA, USA); Primary antibody against full length caspase-8 (1 : 1000, #1006-1) was purchased from Epitomics (Burlingame, CA, USA). Primary antibodies for c-Myc (1 : 1000, sc-40), AXL (1 : 500, sc-1096), and p53 (1 : 500, sc-98) were purchased from Santa Cruz Biotechnology (San Diego, CA, USA).

2.8. Wound Healing Assay

In vitro wound healing assay was performed using the IBIDI Culture-Inserts (GmbH, Munich, Germany) according to the instruction of manufacture. An IBIDI culture insert consists of two reservoirs separated by a 500 μm thick wall. It was placed into the well of 12-well plate and slightly pressed on the top to ensure tight adhesion. An equal number of A549 cells (70 μL; 3 × 105 cells/mL) were added into the two reservoirs of the same insert. After 24 h, the insert was gently removed creating a gap of 500 μm. The cells were then treated as indicated and the migration was observed and photographed after 12, 24, and 48 h by a digital microscope camera (PAXcam2+, Villa Park, IL, USA) adapted to an inverted microscope (Olympus/CKX31, Tokyo, Japan).

2.9. Photograph of the Cells

The phase-contrast images of cells were photographed by a digital microscope camera (PAXcam2+, Villa Park, IL, USA) adapted to an inverted microscope (Olympus/CKX31, Tokyo, Japan).

2.10. Statistical Analysis

Cell viability and colony formation data are expressed as mean ± SE. In Figures 1(a), 1(c), and 6(c), differences between control and JP-1-treated groups were evaluated by one-way ANOVA followed by Dunnett’s -test. Significance values are represented by single (), double (), and triple () asterisks.

3. Results

3.1. JP-1 Inhibits the Proliferation and Colony Formation of A549 Cells

Firstly, we tested the effects of JP-1 on the proliferation and colony formation of A549 human LADC cells. The result of SRB staining showed that treatment with JP-1 for 72 h significantly decreased the growth of A549 cells in a dose-dependent manner (Figure 1(a)). At doses of 300 and 450 μg/mL, JP-1 reduced the A549 cell viability to 45.1% and 13% of control, respectively (Figure 1(a)). By contrast, the same doses of JP-1 only slightly reduced the cell viability of HS68 primary human fetal foreskin fibroblast cells to 78.7% and 81% of control (Figure 1(a)), respectively, implying the preferential inhibition of cancer cells by JP-1. After treatment with JP-1 (300 μg/mL) for 48 h, significant decrease of A549 cell number accompanied with some detached cells could be observed under microscope (Figure 1(b)). When the dose was increased to 450 μg/mL, marked cell death was observed (Figure 1(b)). Similar result was found in colony formation assay. At dose of 75 μg/mL, JP-1 decreased the number of A549 colonies to 71.5% of control (Figures 1(c) and 1(d)). When the dose was increased to 150 μg/mL, almost no colony was formed (Figures 1(c) and 1(d)).

3.2. JP-1 Induces Apoptotic Sub-G1 Fraction in A549 Cells

After treatment with JP-1 for 48 h, the A549 cells were stained with PI and analyzed by flow cytometry to measure the change in cell-cycle distribution. As shown in Figure 2 and Table 1, JP-1 significantly increased the apoptotic sub-G1 fraction from 1.9% in control group to 15.6% and 63.8% at dose of 300 and 450 μg/mL, respectively. Apoptosis induction apparently plays an important role in JP-1-mediated suppression of A549 cells and the cell-cycle might be inhibited by JP-1 via induction of the cyclin-dependent kinase (CDK) inhibitor.

TreatmentCell-cycle distribution
Sub-G1 (%)G0/G1 (%)S (%)G2/M (%)

JP-1 150 μg/mL2.867.914.313.9
JP-1 300 μg/mL15.656.414.012.4
JP-1 450 μg/mL63.826.16.13.7

3.3. JP-1 Decreases CDK6 Protein and Activates the AMPK Pathway in A549 Cells

We then examined the levels of proteins that regulate cell-cycle progression and signaling transduction in JP-1-treated A549 cells. After 48 h of treatment, JP-1 dose-dependently decreased the protein levels of CDK6 (Figure 3(a)). CDK6 was known to promote the phosphorylation of tumor-suppressive retinoblastoma protein (pRb) to inactivate its function in constraining cell-cycle progression [25]. In accordance with this, the phosphorylated pRb (p-pRb) was decreased by JP-1 in a dose-dependent manner (Figure 3(a)). In the aspect of signaling pathway modulation, JP-1 activated the AMPK (AMP-activated protein kinase) signaling pathway. The phosphorylated/activated AMPKα protein (p-AMPKα) was increased after treatment with JP-1 for 48 h (Figure 3(b)). AMPK is a well-known cellular energy sensor, which can be activated by the rise of AMP/ATP ratio [26]. The activated AMPK can inhibit the activity of mTOR (mammalian target of rapamycin), which, in turn, inhibits cell proliferation and protein synthesis [27]. Accordingly, the protein level of phosphorylated/activated mTOR (p-mTOR) in JP-1-treated cells was reduced significantly in a dose-dependent manner (Figure 3(b)). JP-1 might induce metabolic stress in cancer cells, resulting in the activation of tumor suppressors.

3.4. JP-1 Induces p53 and Its Downstream Effectors p21 and BAX in A549 Cells

As AMPK is involved in the activation of p53 [28], an important tumor suppressor and attractive cancer therapeutic target [5], we therefore examined if this powerful transcription factor plays a role in the anticancer activities of JP-1. As expected, the p53 protein level in A549 cells was increased by JP-1 treatment in a time- and dose-dependent manner (Figure 4(a)). Accordingly, its well-known downstream target p21 [15] protein was also induced in a similar manner (Figure 4(b)). In parallel, another p53 downstream, BAX [15], was also increased by JP-1 in a dose-dependent manner (Figure 4(c)). As p21 is a pan CDK inhibitor, which constrains the progression of cell-cycle [15, 29] and BAX can promote the intrinsic/mitochondrial apoptotic pathway [30], the induction of these two proteins was in accordance with the JP-1-mediated growth inhibition and apoptosis induction shown in Figures 1 and 2. In line with this, the increases of cleaved forms of caspase-9, PARP (Poly ADP-ribose polymerase), and caspase-3 and the decrease of full length caspase-8 were observed in JP-1-treated A549 cells (Figure 4(d)). Both the intrinsic (caspase-9) and the extrinsic (caspase-8) apoptosis pathways were activated by JP-1 in A549 cells.

3.5. JP-1 Increases the Transcription of miR-34a Accompanied by the Suppression of Its Downstream Targets Required for Proliferation and Apoptosis Resistance in A549 Cells

In addition to the p21 and BAX, p53 also is reported to activate the transcription of miR-34a, a potent tumor-suppressive miR, which gains much attention in recent cancer researches [20, 31]. This triggers our interest to investigate the effect of JP-1 on miR-34a transcription. As shown in Figure 5(a), JP-1 dose-dependently increased the transcription of miR-34a in A549 cells along with the induction of p53. As miR-34a has been shown to repress its downstream targets required for cell-cycle progression (c-Myc) and apoptosis resistance (SIRT1 and survivin) [21], we then investigated the changes of these proteins after JP-1 treatment. As expected, significant decreases of SIRT1, c-Myc, and survivin were observed in JP-1-treated A549 cells (Figure 5(b)). The apoptosis induction shown in Figure 2 and Table 1 might be also attributed to the downregulation of these proteins.

3.6. JP-1 Downregulates the miR-34a Targets Controlling EMT and Inhibits Migration in A549 Cells

MiR-34a also represses the EMT inducer (AXL) [32] and marker (Snail) [33], and this phenomenon has been demonstrated in A549 cells [33, 34]. We thus examined the effect of JP-1 on these two proteins. As expected, JP-1 dose-dependently decreased AXL and Snail proteins after 48 h of treatment (Figure 6(a)). Moreover, it has been shown that repression of Snail by p53/miR-34a axis in A549 cells would result in decrease of Vimentin (EMT marker) expression [33]. In agreement, significant decrease of Vimentin protein level was also found in these JP-1-treated A549 cells (Figure 6(a)). Prompted by the aforementioned results, we examined the effect of JP-1 on the migration of A549 cells. An in vitro wound healing assay was performed using IBIDI culture insert as described in Section 2. Assessment of wound closure 48 h after starting of the experiment revealed markedly inhibited migration of JP-1-treated cells into the cell free gap in comparison to the control (Figure 6(b)), while no growth inhibition effect of JP-1 occurred in this experimental condition (Figure 6(c)).

Collectively, as shown in Scheme 1, the mechanism of action underlying the anticancer activities of JP-1 is proposed mainly through the activation of p53/miR-34a axis to modulate proteins related to cell-cycle regulation, apoptosis induction, and EMT.

4. Discussion

The incidence of LADC has increased markedly in the past several decades. It has replaced squamous cell carcinoma as the most prevalent type of lung cancer [35]. In spite of the progress of molecular targeted therapy, the drug resistance develops in most patients and more than 50% of LADC patients still lack targetable mutations, demanding alternative therapeutic approaches [36]. Activation of the tumor suppressor p53 by blocking its negative regulator MDM2 is regarded as an attractive approach for cancer therapy [7]. Preclinical study has demonstrated the anticancer effects of small molecule MDM2 inhibitor both in A549 cells and in patient-derived lung cancer xenograft [37]. Although a variety of MDM2 inhibitors have entered into early phase clinical trials [38], they are still not clinically available nowadays. The toxicity may limit their future clinical use. By contrast, the Chinese herbal medicine often possesses advantages of low toxicity. JP-1 only had mild effect on the growth of HS68 human primary foreskin fibroblast cells as compared to its marked antiproliferation and apoptosis-induction activities in A549 cells. For timely treatment of advanced LADC patients refractory to conventional treatments, the Chinese herbal medicine with activity of restoring p53 level is a potential alternative therapeutic strategy for this demand. In support of this notion, our results demonstrate that the Chinese herbal formula JP-1 used for the complementary treatment of LADC could profoundly upregulate the p53 and its downstream targets in A549 LADC cells during apoptosis induction.

Physiologically, p53 can be activated in response to DNA damage, hypoxia, or oncogenic stress. Besides, there is increasing evidence showing that p53 can also be induced by pharmacological or physiological activation of AMPK (AMP-activated protein kinase), a central cellular energy sensor and metabolic switch, which is activated in response to energy crisis [26, 28, 39, 40]. The activated AMPK promotes phosphorylation and acetylation of p53 to prevent it from being repressed by its negative regulator, leading to cell-cycle arrest or apoptosis of cancer cells [28, 40, 41]. Emerging evidence indicates that cancer is primarily a metabolic disease with disturbances in energy production [42, 43]. Targeting cancer metabolism by AMPK activation has become an attractive strategy for cancer therapy [43, 44]. In JP-1-treated A549 cells, the induction of AMPKα phosphorylation was accompanied with significant increase of p53. It is deduced that the activation of AMPK by JP-1 might stabilize p53 through phosphorylation and acetylation, resulting in its accumulation. Further study is warranted to investigate the role of AMPK on the induction of p53 by JP-1.

In addition to the well-known p53 downstream targets such as p21 and BAX, we further unveil the effect of JP-1 on the transcription of miR-34a, which is recently regarded as a novel therapeutic target for LADC [23, 24]. MiR-34a is the first identified and well-studied miR in the p53 regulatory network [20, 31]. Owing to its established role in cancer, synthetic miR-34a mimics are currently in Phase I clinical trials for lung and a variety of types of cancers (NCT01829971) [31]. However, effective delivery of miR-34a mimics to solid tumors is limited by factors, including reticuloendothelial system clearance and nuclease degradation [18]. To overcome this limitation, suitable nanoparticle devices were developed to efficiently encapsulate the miR-34a mimics and protect them from the enzymatic degradation. A lipid/polymer nanoparticle named 7C1 has been employed to deliver miR-34a mimic for treatment of lung tumor in animal model [18]. In parallel, nanoplexes such as chitosan/PLGA (Poly(D,L-lactide-co-glycolide)) and SNALPs (stable nucleic acid lipid particles) have been used for the delivery of miR-34a mimics to treat multiple myeloma xenografts in SCID mice [45, 46]. Regarding the elevated miR-34a transcription and significant repression of its downstream targets in JP-1-treated A549 cells, our results suggest the alternative approach for restoring the miR-34a level in p53 wild-type cancers by treatment with Chinese herbal formula such as JP-1.

Chemotherapy and radiotherapy remain the two main streams of treatment for LADC. It is reported that miR-34a sensitizes A549 cells to cisplatin treatment [47] and in vivo delivery of miR-34a enhances the radiosensitivity of lung tumors through downregulation of the double-strand-break repair protein Rad51 [48]. By increasing the miR-34a transcription, JP-1 might enhance the anticancer effects of cisplatin and radiotherapy.

Another obstacle for successful treatment of cancer is the existence of cancer stem cell (CSC) population. It has been reported that the CD44 (high) tumorigenic subsets in lung cancer biospecimens are enriched for low miR-34a expression [49]. In xenograft tumor model, miR-34a has been shown to negatively regulate the tumorigenic properties of high CD44 expression lung CSCs [22]. In line with these reports, the miR-34a inducer p53 is regarded as the barrier to CSC formation [50]. Compared to normal tissues, A549 cells were shown to possess lower miR-34a level [51]. Similar result was also found by Ma et al. when comparing A549 to the nontumorigenic bronchial epithelium cell line BEAS-2B [52]. The effects of JP-1 on the activation of p53/miR-34a axis shown in this study imply its potential in CSC elimination, which might contribute to the clinical benefit observed in patients.

On the other hand, activation of p53 also modulates the immunity. Previous studies have shown that p53 regulates inflammatory cytokines, toll-like receptors, and IFN signaling and modulates the activation of T-cells and NK cells [53]. By transactivation of miR-34a, p53 was recently shown to repress the expression of programmed cell death-ligand 1 (PD-L1), which is overexpressed in many human cancers, promoting T-cell tolerance and escaping host immunity [53]. Targeting the programmed cell death 1 (PD1)/programmed cell death-ligand 1 (PD-L1) pathway to improve the host immunity is a recent breakthrough in cancer immunotherapy and the clinical benefits have been reported in lung cancer [36]. The repression of PDL1 by miR-34a has been demonstrated in lung cancer cell lines, including A549 [53]. Based on the effects of JP-1 shown in this study, modulation of PDL1 might also be part of the JP-1-activated p53/miR-34a tumor suppressor axis.

According to the foregoing discussion, the potential of JP-1 in the enhancement of conventional cancer therapies, CSC elimination, and immunotherapy deserve in-depth studies and future clinical trials.

5. Conclusion

Our results demonstrate that JP-1 activates p53 and its downstream targets such as p21, BAX, and miR-34a in A549 LADC cells. Accordingly, the suppression of miR-34a downstream targets such as CDK6, SIRT1, c-Myc, survivin, Snail, and AXL are observed. This activation of p53/miR-34a axis is proposed to the main mechanism underlying JP-1-mediated anticancer effects. Regarding the recent reported crucial anticancer activities of miR-34a, more comprehensive investigation coupled with clinical trials is warranted for the sake of integrating JP-1 into complementary cancer therapy.


CDK:Cyclin-dependent kinase
GAPDH:Glyceraldehyde-3-phosphate dehydrogenase
LADC:Lung adenocarcinoma
PBS:Phosphate buffered saline
PBST:Phosphate buffered saline with tween 20
SE:Standard error
SRB:Sulforhodamine B.

Competing Interests

The authors declare no competing interests.

Authors’ Contributions

Gi-Ming Lai and Kuan-Jen Bai equally contributed to the paper.


The authors would like to thank Peter Sheng M.D. Inc. for providing the JP-1 powder. This work was supported by the joint grant of Peter Sheng M.D. Inc., Cincinnati, Ohio, USA, and Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan (Grant W328) and Health and Welfare Surcharge of Tobacco Products, Taiwan (MOHW105-TDU-B-212-134001).


  1. G. Roscilli, C. De Vitis, F. F. Ferrara et al., “Human lung adenocarcinoma cell cultures derived from malignant pleural effusions as model system to predict patients chemosensitivity,” Journal of Translational Medicine, vol. 14, article 61, no. 1, 2016. View at: Publisher Site | Google Scholar
  2. J. Ferlay, H.-R. Shin, F. Bray, D. Forman, C. Mathers, and D. M. Parkin, “Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008,” International Journal of Cancer, vol. 127, no. 12, pp. 2893–2917, 2010. View at: Publisher Site | Google Scholar
  3. C. Chao, M. Lin, C. Fang et al., “Gene therapy for human lung adenocarcinoma using a suicide gene driven by a lung-specific promoter delivered by JC virus-like particles,” PLoS One, vol. 11, no. 6, Article ID e0157865, 2016. View at: Publisher Site | Google Scholar
  4. L. Chen, G. Kong, C. Zhang et al., “MicroRNA-432 functions as a tumor suppressor gene through targeting E2F3 and AXL in lung adenocarcinoma,” Oncotarget, vol. 7, no. 15, pp. 20041–20053, 2016. View at: Publisher Site | Google Scholar
  5. S. Shangary and S. Wang, “Targeting the MDM2-p53 interaction for cancer therapy,” Clinical Cancer Research, vol. 14, no. 17, pp. 5318–5324, 2008. View at: Publisher Site | Google Scholar
  6. P. Chène, “Inhibiting the p53-MDM2 interaction: an important target for cancer therapy,” Nature Reviews Cancer, vol. 3, no. 2, pp. 102–109, 2003. View at: Publisher Site | Google Scholar
  7. M. Wade, Y.-C. Li, and G. M. Wahl, “MDM2, MDMX and p53 in oncogenesis and cancer therapy,” Nature Reviews Cancer, vol. 13, no. 2, pp. 83–96, 2013. View at: Publisher Site | Google Scholar
  8. Y. Zhang, H. Dong, Z. Li et al., “Bing De Ling®, a Chinese herbal formula, inhibits cancer cells growth via p53,” Frontiers in Bioscience—Elite, vol. 2, no. 1, pp. 221–230, 2010. View at: Google Scholar
  9. J. A. Vaz, I. C. F. R. Ferreira, C. Tavares, G. M. Almeida, A. Martins, and M. Helena Vasconcelos, “Suillus collinitus methanolic extract increases p53 expression and causes cell cycle arrest and apoptosis in a breast cancer cell line,” Food Chemistry, vol. 135, no. 2, pp. 596–602, 2012. View at: Publisher Site | Google Scholar
  10. Y.-H. Lan, J.-H. Chiang, W.-W. Huang et al., “Activations of both extrinsic and intrinsic pathways in HCT 116 human colorectal cancer cells contribute to apoptosis through p53-mediated ATM/Fas signaling by Emilia sonchifolia extract, a folklore medicinal plant,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 178178, 13 pages, 2012. View at: Publisher Site | Google Scholar
  11. H.-R. Liu, L.-Y. Meng, Z.-Y. Lin, Y. Shen, Y.-Q. Yu, and Y.-Z. Zhu, “Cochinchina momordica seed extract induces apoptosis and cell cycle arrest in human gastric cancer cells via PARP and p53 signal pathways,” Nutrition and Cancer, vol. 64, no. 7, pp. 1070–1077, 2012. View at: Publisher Site | Google Scholar
  12. J. Gao, W. A. Morgan, A. Sanchez-Medina, and O. Corcoran, “The ethanol extract of Scutellaria baicalensis and the active compounds induce cell cycle arrest and apoptosis including upregulation of p53 and Bax in human lung cancer cells,” Toxicology and Applied Pharmacology, vol. 254, no. 3, pp. 221–228, 2011. View at: Publisher Site | Google Scholar
  13. Y.-L. Cheng, S.-C. Lee, H.-J. Harn, H.-C. Huang, and W.-L. Chang, “The extract of Hibiscus syriacus inducing apoptosis by activating p53 and AIF in human lung cancer cells,” American Journal of Chinese Medicine, vol. 36, no. 1, pp. 171–184, 2008. View at: Publisher Site | Google Scholar
  14. A. Mirza, M. McGuirk, T. N. Hockenberry et al., “Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway,” Oncogene, vol. 21, no. 17, pp. 2613–2622, 2002. View at: Publisher Site | Google Scholar
  15. X. He, L. He, and G. J. Hannon, “The guardian's little helper: microRNAs in the p53 tumor suppressor network,” Cancer Research, vol. 67, no. 23, pp. 11099–11101, 2007. View at: Publisher Site | Google Scholar
  16. L. He and G. J. Hannon, “MicroRNAs: small RNAs with a big role in gene regulation,” Nature Reviews Genetics, vol. 5, no. 7, pp. 522–531, 2004. View at: Publisher Site | Google Scholar
  17. K. Valencia, D. Luis-Ravelo, N. Bovy et al., “MiRNA cargo within exosome-like vesicle transfer influences metastatic bone colonization,” Molecular Oncology, vol. 8, no. 3, pp. 689–703, 2014. View at: Publisher Site | Google Scholar
  18. W. Xue, J. E. Dahlman, T. Tammela et al., “Small RNA combination therapy for lung cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 34, pp. E3553–E3561, 2014. View at: Publisher Site | Google Scholar
  19. F. Sun, H. Fu, Q. Liu et al., “Downregulation of CCND1 and CDK6 by miR-34a induces cell cycle arrest,” FEBS Letters, vol. 582, no. 10, pp. 1564–1568, 2008. View at: Publisher Site | Google Scholar
  20. N. Okada, C.-P. Lin, M. C. Ribeiro et al., “A positive feedback between p53 and miR-34 miRNAs mediates tumor suppression,” Genes and Development, vol. 28, no. 5, pp. 438–450, 2014. View at: Publisher Site | Google Scholar
  21. G. Misso, M. T. Di Martino, G. De Rosa et al., “Mir-34: a new weapon against cancer?” Molecular Therapy—Nucleic Acids, vol. 3, article e194, 2014. View at: Publisher Site | Google Scholar
  22. Y. Shi, C. Liu, X. Liu, D. G. Tang, and J. Wang, “The microRNA miR-34a inhibits non-small cell lung cancer (NSCLC) growth and the CD44hi stem-like NSCLC cells,” PLoS ONE, vol. 9, no. 3, Article ID e90022, 2014. View at: Publisher Site | Google Scholar
  23. A. L. Kasinski and F. J. Slack, “miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma,” Cancer Research, vol. 72, no. 21, pp. 5576–5587, 2012. View at: Publisher Site | Google Scholar
  24. J. F. Wiggins, L. Ruffino, K. Kelnar et al., “Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34,” Cancer Research, vol. 70, no. 14, pp. 5923–5930, 2010. View at: Publisher Site | Google Scholar
  25. C. Giacinti and A. Giordano, “RB and cell cycle progression,” Oncogene, vol. 25, no. 38, pp. 5220–5227, 2006. View at: Publisher Site | Google Scholar
  26. Y. Adamovich, J. Adler, V. Meltser, N. Reuven, and Y. Shaul, “AMPK couples p73 with p53 in cell fate decision,” Cell Death and Differentiation, vol. 21, no. 9, pp. 1451–1459, 2014. View at: Publisher Site | Google Scholar
  27. W. Wang and K.-L. Guan, “AMP-activated protein kinase and cancer,” Acta Physiologica, vol. 196, no. 1, pp. 55–63, 2009. View at: Publisher Site | Google Scholar
  28. R. Okoshi, T. Ozaki, H. Yamamoto et al., “Activation of AMP-activated protein kinase induces p53-dependent apoptotic cell death in response to energetic stress,” The Journal of Biological Chemistry, vol. 283, no. 7, pp. 3979–3987, 2008. View at: Publisher Site | Google Scholar
  29. B. Huang, D. Deo, M. Xia, and L. T. Vassilev, “Pharmacologic p53 activation blocks cell cycle progression but fails to induce senescence in epithelial cancer cells,” Molecular Cancer Research, vol. 7, no. 9, pp. 1497–1509, 2009. View at: Publisher Site | Google Scholar
  30. S. Zamorano, D. Rojas-Rivera, F. Lisbona et al., “A BAX/BAK and cyclophilin D-independent intrinsic apoptosis pathway,” PLoS ONE, vol. 7, no. 6, Article ID e37782, 2012. View at: Publisher Site | Google Scholar
  31. N. Samuel, G. Wilson, B. I. Said et al., “Transcriptome-wide characterization of the endogenous miR-34A-p53 tumor suppressor network,” Oncotarget, vol. 7, no. 3, pp. 49611–49622, 2016. View at: Publisher Site | Google Scholar
  32. M. K. Asiedu, F. D. Beauchamp-Perez, J. N. Ingle, M. D. Behrens, D. C. Radisky, and K. L. Knutson, “AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells,” Oncogene, vol. 33, no. 10, pp. 1316–1324, 2014. View at: Publisher Site | Google Scholar
  33. N. H. Kim, H. S. Kim, X.-Y. Li et al., “A p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial-mesenchymal transition,” Journal of Cell Biology, vol. 195, no. 3, pp. 417–433, 2011. View at: Publisher Site | Google Scholar
  34. J.-H. Lee, J. Voortman, A.-M. C. Dingemans et al., “MicroRNA expression and clinical outcome of small cell lung cancer,” PLoS ONE, vol. 6, no. 6, Article ID e21300, 2011. View at: Publisher Site | Google Scholar
  35. C. S. Dela Cruz, L. T. Tanoue, and R. A. Matthay, “Lung cancer: epidemiology, etiology, and prevention,” Clinics in Chest Medicine, vol. 32, no. 4, pp. 605–644, 2011. View at: Publisher Site | Google Scholar
  36. Y. J. Cha, H. R. Kim, C. Y. Lee, B. C. Cho, and H. S. Shim, “Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status,” Lung Cancer, vol. 97, pp. 73–80, 2016. View at: Publisher Site | Google Scholar
  37. J. Hai, S. Sakashita, G. Allo et al., “Inhibiting MDM2-p53 interaction suppresses tumor growth in patient-derived non-small cell lung cancer xenograft models,” Journal of Thoracic Oncology, vol. 10, no. 8, pp. 1172–1180, 2015. View at: Publisher Site | Google Scholar
  38. A. Burgess, K. M. Chia, S. Haupt, D. Thomas, Y. Haupt, and E. Lim, “Clinical overview of MDM2/X-targeted therapies,” Frontiers in Oncology, vol. 6, article no. 7, 2016. View at: Publisher Site | Google Scholar
  39. K. Imamura, T. Ogura, A. Kishimoto, M. Kaminishi, and H. Esumi, “Cell cycle regulation via p53 phosphorylation by a 5′-AMP activated protein kinase activator, 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside, in a human hepatocellular carcinoma cell line,” Biochemical and Biophysical Research Communications, vol. 287, no. 2, pp. 562–567, 2001. View at: Publisher Site | Google Scholar
  40. R. G. Jones, D. R. Plas, S. Kubek et al., “AMP-activated protein kinase induces a p53-dependent metabolic checkpoint,” Molecular Cell, vol. 18, no. 3, pp. 283–293, 2005. View at: Publisher Site | Google Scholar
  41. C.-W. Lee, L. L.-Y. Wong, E. Y.-T. Tse et al., “AMPK promotes p53 acetylation via phosphorylation and inactivation of SIRT1 in liver cancer cells,” Cancer Research, vol. 72, no. 17, pp. 4394–4404, 2012. View at: Publisher Site | Google Scholar
  42. T. N. Seyfried, R. E. Flores, A. M. Poff, and D. P. D'Agostino, “Cancer as a metabolic disease: implications for novel therapeutics,” Carcinogenesis, vol. 35, no. 3, Article ID bgt480, pp. 515–527, 2014. View at: Publisher Site | Google Scholar
  43. D. G. Hardie and D. R. Alessi, “LKB1 and AMPK and the cancer-metabolism link—ten years after,” BMC Biology, vol. 11, article 36, 2013. View at: Publisher Site | Google Scholar
  44. K.-H. Lee, E.-C. Hsu, J.-H. Guh et al., “Targeting energy metabolic and oncogenic signaling pathways in triple-negative breast cancer by a novel adenosine monophosphate-activated protein kinase (AMPK) activator,” The Journal of Biological Chemistry, vol. 286, no. 45, pp. 39247–39258, 2011. View at: Publisher Site | Google Scholar
  45. M. T. Di Martino, V. Campani, G. Misso et al., “In vivo activity of MiR-34a mimics delivered by stable nucleic acid lipid particles (SNALPs) against multiple myeloma,” PLOS ONE, vol. 9, no. 2, Article ID e90005, 2014. View at: Publisher Site | Google Scholar
  46. D. Cosco, F. Cilurzo, J. Maiuolo et al., “Delivery of miR-34a by chitosan/PLGA nanoplexes for the anticancer treatment of multiple myeloma,” Scientific Reports, vol. 5, Article ID 17579, 2015. View at: Publisher Site | Google Scholar
  47. X. Wang, K. Dong, P. Gao et al., “microRNA-34a sensitizes lung cancer cell lines to DDP treatment independent of p53 status,” Cancer Biotherapy and Radiopharmaceuticals, vol. 28, no. 1, pp. 45–50, 2013. View at: Publisher Site | Google Scholar
  48. M. A. Cortez, D. Valdecanas, S. Niknam et al., “In vivo delivery of miR-34a sensitizes lung tumors to radiation through RAD51 regulation,” Molecular Therapy—Nucleic Acids, vol. 4, no. 12, article e270, 2015. View at: Publisher Site | Google Scholar
  49. S. K. Basak, M. S. Veena, S. Oh et al., “The CD44high tumorigenic subsets in lung cancer biospecimens are enriched for low miR-34a expression,” PLoS ONE, vol. 8, no. 9, Article ID e73195, 2013. View at: Publisher Site | Google Scholar
  50. R. Aloni-Grinstein, Y. Shetzer, T. Kaufman, and V. Rotter, “p53: the barrier to cancer stem cell formation,” FEBS Letters, vol. 588, no. 16, pp. 2580–2589, 2014. View at: Publisher Site | Google Scholar
  51. E. Tafsiri, M. Darbouy, M. Shadmehr, W. Cho, and M. Karimipoor, “Abberent expression of oncogenic and tumor-suppressive microRNAs and their target genes in human adenocarcinoma alveolar basal epithelial cells,” Journal of Cancer Research and Therapeutics, vol. 12, no. 1, pp. 395–400, 2016. View at: Publisher Site | Google Scholar
  52. Z.-L. Ma, P.-P. Hou, Y.-L. Li et al., “MicroRNA-34a inhibits the proliferation and promotes the apoptosis of non-small cell lung cancer H1299 cell line by targeting TGFβR2,” Tumor Biology, vol. 36, no. 4, pp. 2481–2490, 2015. View at: Publisher Site | Google Scholar
  53. M. A. Cortez, C. Ivan, D. Valdecanas et al., “PDL1 regulation by p53 via miR-34,” Journal of the National Cancer Institute, vol. 108, no. 1, Article ID djv303, 2016. View at: Publisher Site | Google Scholar

Copyright © 2016 Chih-Jung Yao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

911 Views | 501 Downloads | 5 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.